SNX10 and precursor B-cell acute lymphoblastic leukemia: These findings provide novel insights into the potential of SNX10 as a prognostic marker and therapeutic target for the management of B-ALL, supporting further research into SNX10-modulating therapies that could improve treatment outcomes for patients with B-ALL.